Purpose of review Nonalcoholic fatty liver disease (NAFLD) is a liver disease with high prevalence in western countries. Progression from NAFLD to nonalcoholic steatohepatitis (NASH) occurs in 10-20%. NASH pathogenesis is multifactorial including genetic and environmental factors. The gut microbiota is involved in disease progression and its role is complex.
INTRODUCTION
The intestine harbors a large quantity of microbes including bacteria, archaea, viruses and fungi. It is estimated that the number of bacteria in the human body equals the number of human cells [1 & ]. Hepatologists have appreciated the existence of a gutliver axis for quite some time. Reports in the 1950s showed that nonabsorbable antibiotics prevent cirrhosis in an animal model of nonalcoholic steatohepatitis (NASH) [2] . More direct evidence for the contribution of intestinal bacteria to progression of liver disease was observed with the advent of nextgeneration sequencing technologies for microbiota analysis and with new experimental approaches. Such novel approaches included the use of germfree mice that were resistant to high-fat diet-induced obesity and hepatic steatosis [3] . Seminal findings showed that the obesity phenotype is transmissible. Germ-free mice transplanted with feces from an obese donor accumulated more fat as compared to germ-free mice receiving feces from a lean donor [4] . Similarly, microbial transfer can result in the development of exacerbated NASH in mice [5] . In recent years, compositional changes in the intestinal microbiota have been proposed to mechanistically contribute to obesity, nonalcoholic fatty liver disease (NAFLD) and NASH. Mechanisms include increased energy harvest by the microbiota from an obese individual, higher short chain fatty acid (SCFA) production, dysbiosis-induced intestinal inflammation, gut barrier dysfunction and regulation of appetite and modulation of the host immune system [6, 7] . Some of these changes appear to be relevant for mice, but not for humans [8] .
This review summarizes ties between intestinal microbiota changes and the development of NASH that have been discovered over the last 2 years. We
Intestinal microbiota changes in patients with nonalcoholic steatohepatitis
Various liver diseases including NASH are associated with intestinal dysbiosis [9] . Gut microbiota affects digestion and absorption of nutrients, the host immune system and the production of gut hormones [10] . Human microbiota studies in NASH are sparse with only very few reports demonstrating an association between gut dysbiosis and NASH. In a recent study, two genera, Bacteroides and Prevotella were significantly different in fecal samples of NASH patients compared with healthy controls [11 & ]. Although Bacteroides had a higher abundance and were independently associated with NASH, proportions of Prevotella were lower in NASH patients. Bacteroides and Prevotella act as competitors and have an inverse relationship [12] . Dietary composition can influence this balance and western diets rich in fat, animal proteins and sugar modulate Bacteroides [13] and have been associated with NASH [14] . Apart from diet, several other factors could explain altered proportions of Bacteroides in NASH. Abundance of Bacteroides correlated with increased levels of oligosaccharides (that contain glucose and fructose), D-pinitol, and deoxycholic acid. Deoxycholic acid can induce apoptosis in rat livers [15] and is found in higher levels in human livers with NASH [16] , fructose promotes liver inflammation and fibrosis [17] . In addition, Bacteroides abundance correlated with decreased levels of short chain fatty acids (SCFA) and amino acids [18] .
A subanalysis looking at microbiota changes associated with fibrosis severity demonstrated an independent association of Ruminococcus abundance with fibrosis F2 [11 & ]. Ruminococci populations can be affected by diet [19] . As the Rumiococcus genus is very heterogeneous including both beneficial and deleterious bacteria, a mechanism linking Ruminococcus abundance with fibrosis is not yet clear and requires further studies. In contrast to the above cited report in adults with NASH, two recent studies in children with NASH demonstrated different results [20 & ,21] . In contrast to the adult samples detecting differences only at the genera level, one study demonstrated differences at the phylum, family and genera level in fecal samples of children with NASH. Proportions of Proteobacteria/Enterobacteriaceae/Escherichia were higher in pediatric NASH patients compared with healthy controls and obese patients [21] . Other genera that showed significant differences between healthy controls and pediatric NASH patients included decreased levels of Alistipes, Blautia, Coprococcus, Eubacterium, Oscillospira and Bifidobacterium [6, 21] . In contrast to adult NASH patients who showed decreased levels of Prevotella, samples from children with NASH demonstrated a significant increase in Prevotella [21] . Another study using pediatric NASH patients found decreased levels of Oscillospira and, in line with the study using adult patients, increased levels of Ruminococcus. Other genera that were significantly different in pediatric NASH patients versus healthy controls included increased levels of Dorea and Blautia [20 & ]. Differences in these various studies may in part be explained by the small sample size, differences in age (adults versus children), diet and diagnostic criteria.
Patients with NAFLD and NASH do not only show compositional changes in the gut microbiota, but also bacterial overgrowth in the small intestine. The prevalence of small intestinal bacterial overgrowth is 60% in patients with NAFLD, which is increased when compared with healthy controls (21%). However, there was no significant correlation between small intestinal bacterial overgrowth and the presence of NASH, lobular inflammation or fibrosis score within the NAFLD patient cohort [22] . Using cultures of duodenal aspirates, small intestinal bacterial overgrowth (defined as colony count above 10 5 CFU/ml) was present in 38% of patients with NAFLD [23] . Patients with small intestinal bacterial overgrowth had significantly higher endotoxin levels, but there was again no association with NASH [23] . A recent preclinical trial emphasized the importance of bacterial overgrowth mediated by a prolonged orofecal transit time in patients with NAFLD and NASH. The promotility agent mosapride improved NASH in mice [24] . Surprisingly, numbers of fecal bacteria were not reduced with mosapride treatment, but compositional changes were observed. This was associated with increased
KEY POINTS
NASH is associated with an altered composition of the intestinal microbiota.
Intestinal inflammation is an important cause for increased intestinal permeability.
Translocation of microbial products contributes to NASH.
Microbial metabolites are altered in humans with NASH and might serve as excellent targets for NASH therapy.
The intestinal microbiota Brandl and Schnabl systemic glucagon-like peptide 1 levels, reduced colonic inflammation and lower serum endotoxin levels [24] .
How does the intestinal microbiota contribute to nonalcoholic steatohepatitis?
Intestinal inflammation and gut barrier dysfunction Several studies have linked gut barrier dysfunction to increased bacterial translocation and hepatic inflammation. One proposed mechanism involves an increased susceptibility to intestinal permeability in patients with NASH [25] . As a consequence, serum endotoxin levels were significantly higher and may be responsible for liver injury in these patients. Presumably, lipopolysaccharide (or endotoxin), derived from the gut microflora, translocates via a dysfunctional gut barrier to the portal vein and liver, thereby inducing an inflammatory response through activation of inflammatory cells in the liver. As a result, mice deficient in Toll-like receptor (TLR)-4 and myeloid-differentiation factor-2 are protected from methionine and choline-deficient diet-induced liver inflammation and fat deposition [26] . Other microbial products might also cause a progression of liver disease. Plasma from mice and patients with NASH contain high levels of mitochondrial DNA, a potent TLR9 activator [27 & ]. A complete deletion of TLR9 and mice deficient in TLR9 on lysosome-producing cells protects from high-fat diet-induced hepatic steatosis and inflammation. Furthermore, a TLR9 antagonist blocked the development of NASH when given prophylactically and therapeutically in mice [27 & ]. Exposure of microbial products to the liver is not necessarily detrimental; some studies also demonstrate a beneficial role of bacterial products. TLR5 recognizes bacterial flagellin. Mice lacking TLR5 on hepatocytes showed exacerbated disease upon methionineand choline-deficient diet, and high-fat diet. TLR5 expressed on hepatocytes plays therefore an important role in the protection of the liver against dietinduced liver disease [28] (Table 1) .
It is not clear, however, if altered permeability is a cause or consequence of endotoxin exposure. A recent study, using mice deficient in the tight junction molecule junctional adhesion molecule (JAM)-A, showed increased intestinal permeability and bacterial translocation to the liver driving hepatic inflammation and NASH. Interestingly, administration of antibiotics abrogated hepatic inflammation and the development of NASH. This clearly demonstrates a role for microbiota in inducing hepatic inflammation. Using endoscopic biopsies from patients with NASH, the authors further showed decreased levels of JAM-A and increased mucosal inflammation in the colon. Genetic disposition leading to defects in the integrity of the epithelial barrier may therefore predispose patients to hepatic inflammation and NASH progression [31 && ]. Apart from genetic predisposition, the inciting event responsible for increased intestinal permeability has not been clearly identified. Intestinal inflammation and the resulting production of several cytokines could play an underlying role in permeability changes [32, 33] . Recent evidence suggests diet-induced obesity as a trigger of intestinal inflammation and insulin resistance [34 && ]. A proinflammatory shift in gut immune cell populations was demonstrated in mice upon high-fat diet feeding and obese humans. Treatment with 5-aminosalicylic acid (5-ASA) that acts as a gut antiinflammatory agent reduced bowel inflammation and insulin resistance in mice. Interestingly, 5-ASA treatment also significantly improved intestinal permeability and reduced liver steatosis [34 && ] further providing evidence for a link between intestinal inflammation, changes in gut permeability and progression of liver disease. Increased intestinal inflammation is also present in patients with NAFLD as exemplified by intestinal tight junction disruption, changes in immune cell populations and increased intestinal cytokine levels [35] .
Bacterial metabolites
As diagnosis of NASH requires a liver biopsy, extensive efforts have been made to find noninvasive, sensitive methods to detect early stages of disease and to stage progressive NASH. Bacterial metabolites might serve as biomarkers, but they might also be linked mechanistically to NASH progression. A recent study using pediatric NASH patients demonstrated a unique profile with increased levels of fecal 2-butanone and 4-methyl-2-pentanone. Together with the observed metagenomics data (lower levels of Oscillospira and high abundances of Blautia, Dorea and Ruminococcus), this unique signature could serve as potential biomarker [20 & ]. Another important metabolite that has been associated with progression of NAFLD is ethanol. Both pediatric NASH [21] and NAFLD [36] patients exhibited significantly increased blood ethanol levels. Of note, serum ethanol levels in pediatric NASH patients (average 0.00016 g/dl, calculated based on fig. 4 [21]) were 1000 times lower than plasma ethanol levels in children with NAFLD (average 0.115 g/dl, calculated based on Fig. 1 [36] ). Although such low ethanol levels are likely not important contributors to liver disease progression, reported levels in NAFLD are above the legal limit for driving in the United States. Technical problems in measuring blood ethanol levels might account for these differences. Different mechanisms have been proposed for elevated blood ethanol levels. One hypothesis to explain the differences in blood ethanol is the increased abundance of ethanol producing bacteria that have been detected in NASH microbiomes [21] . In contrast, another study suggests that alterations in insulin signaling followed by decreased alcohol dehydrogenase activity in the liver are responsible for an impaired ethanol metabolism [36] . Future studies are required to determine the role of ethanol for progression of NAFLD and NASH.
Bile acids
Bile acids are derived from cholesterol and synthesized in the liver through a series of reactions involving cytochrome P450 (CYP) enzymes. After these oxidative processes, bile acids are conjugated with the amino acids taurine or glycine and secreted into the intestine after a meal. In the intestine, they have major functions in lipid solubilization and digestion. The majority (90%) of luminal conjugated primary bile acids are actively reabsorbed in the terminal ileum. The remaining luminal bile FIGURE 1. Gut-derived products that contribute to NASH progression. Intestinal products reaching the liver can have multifaceted effects on liver physiology. Increased levels of microbial products, ethanol and an altered bile acid profile have been detected in patients with NASH. NASH, nonalcoholic steatohepatitis. [37] . Total unconjugated, primary unconjugated bile acids and tauroconjugated lithocholic acid were higher in feces of patients with NASH [38] . In addition to their digestive functions, they regulate their own synthesis by stimulating the nuclear receptor farnesoid x receptor (FXR) in ileal enterocytes and releasing fibroblast growth factor (FGF)-19 into the portal circulation. FGF19 reaches hepatocytes and suppresses the ratelimiting enzyme in the bile acid synthesis pathway, CYP7A1 [39] . Serum FGF19 was not different between NASH patients and healthy controls [38] indicating that changes in intestinal bile acid composition did not alter FXR activity in the ileum. Despite unchanged FGF19 levels, serum C4 (a bile acid intermediate and indicator of de-novo biosynthesis of bile acids in the liver) was elevated in NASH compared with healthy controls [38] indicating that increased bile acid synthesis is unlikely driven by intestinal dysbiosis (Table 1) . Bile acids are ligands not only for the nuclear receptor FXR, but also for several other receptors including the cell membrane G-protein-coupled bile acid receptor 1 (also called TGR5 for Takeda G-protein-coupled receptor 5). Bile acids are important regulators of glucose and lipid metabolism, thermogenesis and inflammation (recent reviews [39, 40] ). The bile acid derivative 6-ethylchenodeoxycholic acid (obeticholic acid) is a potent activator of FXR. A double-blind, placebo-controlled, randomized clinical trial showed improved histological features in patients with noncirrhotic NASH patients with obeticholic acid given orally (25 mg daily) for 72 weeks [41 && ]. A higher number of patients treated with obeticholic acid had improvement in fibrosis, hepatocellular ballooning, steatosis and lobular inflammation [41 && ]. Treatment with obeticholic acid was associated with higher concentrations of total serum cholesterol and LDL cholesterol, and a decrease in HDL cholesterol. The significance of these changes on cardiovascular outcome is not known. In addition, patients treated with obeticholic acid had more pruritus [41 && ]. Newer, non bile acid-based, synthetic FXR agonists are currently being tested that might have fewer side-effects [39] . Thus, bile acids are important communicating molecules between the liver and intestine and can serve as target for therapy. An experimental, intestine restricted FXR agonist, fexaramine, improved hepatic steatosis in mice [30] , although there is controversy about the role of intestinal FXR for lipid metabolism [29] .
CONCLUSION
NASH is a multifactorial disease and overnutrition might be the most important target for therapy. The intestinal microbiota is one of the contributing pathogenic factors (Fig. 1) . NASH is associated with changes in the intestinal microbiota composition and metabolome, intestinal and systemic inflammatory response and bile acid profiles. Altered microbial metabolites might serve as excellent targets for NASH therapy. However, a better characterization of the intestinal microbiota and metabolome in larger and better characterized human cohorts is required. This might identify subgroups of patients for which a tailored microbiome-based therapy might be beneficial. Precision microbiome therapy could include microbiota transplantation with more defined microbial communities, engineered bacterial strains or drugs that target bacterial metabolic pathways. In addition, targeting the inflammatory response or the altered bile acid profile provides other novel therapeutic strategies currently under investigation.
